Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation

Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation

Measurable residual disease (MRD) is increasingly employed as a biomarker of quality of complete remission (CR) in intensively treated acute myeloid leukemia (AML) patients. We evaluated if a MRD-driven transplant policy improved outcome as compared to a policy solely relying on a familiar donor ava...

Full description

Bibliographic Details
Main Authors: Francesco Buccisano, Raffaele Palmieri, Alfonso Piciocchi, Luca Maurillo, Maria Ilaria Del Principe, Giovangiacinto Paterno, Stefano Soddu, Raffaella Cerretti, Gottardo De Angelis, Benedetta Mariotti, Maria Antonietta Irno Consalvo, Consuelo Conti, Daniela Fraboni, Mariadomenica Divona, Tiziana Ottone, Serena Lavorgna, Paola Panetta, Maria Teresa Voso, William Arcese, Adriano Venditti
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
biomarkers
AML
MRD
cytogenetics and molecular markers
multiparametric flow cytometry
Online Access:https://www.mdpi.com/2072-6694/13/5/1083

Internet

https://www.mdpi.com/2072-6694/13/5/1083

Similar Items